The cost implications of a polypill for primary prevention in the TIPS-3 trial
- 28 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 8 (8) , 899-908
Abstract
Aims: The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesterol- and multiple blood-pressure-lowering drugs reduces cardiovascular events by 20% compared with placebo in people without cardiovascular disease. The polypill plus aspirin led to a 31% relative risk reduction in cardiovascular disease events compared with double placebo. We report regional variations in costs and affordability of a polypill based on the TIPS-3 trial. Methods and results: Countries were categorized using World Bank economic groups: lower-middle-income, upper-middle-income, and high-income countries. Country-specific costs were obtained for hospitalization events, procedures, and non-study medications (2019 US dollars). Polypill price was based on the cheapest equivalent substitute (CES) for each component. For the polypill vs. placebo, the difference in cost over the 4.6 years of the trial was $291 [95% confidence interval (CI): $243–339] per participant in lower-middle-income countries, $1068 (95% CI: $992–1144) in upper-middle-income countries, and $48 (95% CI: −$271 to $367) in high-income countries. Results were similar for the polypill plus aspirin vs. a double placebo. In both cases, the polypill was affordable in all groups using monthly household capacity to pay or a threshold of 4% of the gross national income per capita. Conclusion: The use of a polypill (CES) in TIPS-3 increases costs in lower-middle-income countries and upper-middle-income countries but is affordable in countries at various economic levels and is cost neutral (dominant) in high-income countries.Keywords
Funding Information
- AstraZeneca
- Boehringer Ingelheim
- Bristol Myers Squibb
- Coca-Cola India
- Pfizer
- Eli Lilly
- Sanofi
This publication has 16 references indexed in Scilit:
- The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conductAmerican Heart Journal, 2018
- Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological studyThe Lancet Diabetes & Endocrinology, 2018
- Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study dataThe Lancet Public Health, 2017
- Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study dataThe Lancet, 2016
- The Cost Implications of Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery at One YearThe Annals of Thoracic Surgery, 2014
- Practical measurement of affordability: an application to medicinesBulletin of the World Health Organization, 2012
- The Cost of Clopidogrel Use in Atrial Fibrillation in the ACTIVE-A TrialCanadian Journal of Cardiology, 2012
- The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countriesBulletin of the World Health Organization, 2007
- Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticiansStatistics in Medicine, 2000
- The Distribution of Health Care Costs and Their Statistical Analysis for Economic EvaluationJournal of Health Services Research & Policy, 1998